-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Hims & Hers Health Fell 52% Even As Sales Rose

Simply Wall St·11/19/2026 22:08:53
Listen to the news

Hims & Hers Health has not been short of headlines lately, from FTC lawsuits over data sharing to upbeat analyst reports on GLP-1 partnerships and global expansion. For Hims & Hers Health shareholders, the loss over the past year was 52.4%, including dividends. If you had bought in a year ago on the promise of telehealth growth and hormonal health tailwinds, how should you now view a business that is chasing global scale while margins and regulation pull in the opposite direction?

The move put Hims & Hers Health in the middle of this trade. Scan 37 healthcare AI stocks for other companies exposed to it.

The Two Stories Hims & Hers Health Investors Were Weighing

The shares cost US$36.26 at the start of the period, and you had to decide which story about Hims & Hers Health felt more convincing.

On the upbeat side, one thesis saw telehealth and hormonal care reshaping global markets, with a Fair Value of US$47.42, a price level implied by assumptions like 18.8% revenue growth and an 8.1% profit margin over three years.

The more cautious view put Fair Value at US$28, a lower implied price that stressed rising regulatory costs, tougher telehealth competition, and pressure on pricing power as key risks.

NYSE:HIMS 1-Year Stock Price Chart
NYSE:HIMS 1-Year Stock Price Chart

What The Hims & Hers Health Results Put To The Test

The big development was Hims & Hers Health closing the Eucalyptus deal and pushing hard into GLP-1 and peptide therapies, which lined up with the bullish story about global reach and broader treatment categories. Q3 2026 results told a different part of the story. Revenue rose to US$890.4m, but profit turned into a US$33.0m loss and net margin fell to -3.7%, so the profitability piece of the upbeat case stayed unproven. Overall, the evidence cut both ways.

The lesson is simple. When a business leans on scale and new categories to justify optimism, track whether higher sales are turning into a healthier net margin. If the top line grows while profitability slips, treat any story about future earnings strength as a claim to test against the next few reports, not a conclusion.

What Hims & Hers Health’s Drop Leaves You Weighing Today

Hims & Hers Health now trades at US$17.05, with this analyst consensus Narrative on Simply Wall St suggesting Fair Value sits above that level based on its reading of the business and current forecasts.

The Narrative focuses on AI enabled telehealth, GLP-1 weight loss and broader hormonal care to deepen subscriber relationships. A buyer today would need to believe those newer lines can convert rapid expansion into durable, higher margin subscription economics.

"The main thing that has to go right is that Hims & Hers Health turns its rapid expansion in branded GLP-1 weight loss, testosterone, and international operations into durable, higher-margin subscriber relationships despite rising regulatory and payment scrutiny."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

How Could You Get There Earlier?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

  • Company 1 - 38% below our estimate - ties electrical construction capacity to hyperscale data center build schedules.
  • Company 2 - 43% below our estimate - shifts flash output toward higher density enterprise drives for AI workloads.
  • Company 3 - 31% below our estimate - channels new manufacturing lines into AI data center optics and advanced packaging.

Those are three of them. See every one of the 35 undervalued companies on it →